ArticleACS applied materials & interfaces2026
Dual-Targeting iRGD-Functionalized Pentablock Copolymer Nanosystem for miR-345-5p and Gemcitabine Delivery to Pancreatic Tumors.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have remained limited. Conventional chemotherapies for pancreatic cancer (PC) suffer from dose-limiting toxicities and limited efficacy due to drug resistance, poor biodistribution, and extensive desmoplasia. Targeted delivery of microRNAs to modify the tumor microenvironment, in combination with chemotherapeutics, can enhance outcomes by mitigating off-target toxicity and reducing fibrosis and drug resistance associated with PC therapies. To address these challenges, we developed a tumor-guided dual-targeting nanosystem for the codelivery of miR-345 and gemcitabine. This system leverages the intrinsic chemistry of pentablock copolymers for selective endolysosomal escape in tumor cells as well as targeting through functionalization with the tumor-penetrating peptide iRGD (a multifunctional construct referred to as mGP-i). The mGP-i nanosystem exploits both passive and active targeting mechanisms within the tumor microenvironment to enhance the selective uptake and synergistic activity of miR-345 and gemcitabine in pancreatic tumors. The mGP-i nanosystem exhibited stability against RNase degradation and serum proteins for 24 h, with rapid release of gemcitabine over 48 h and prolonged miR-345 release over 1 week. In vivo biodistribution studies following intravenous administration in mice bearing subcutaneous PC tumors showed rapid and selective accumulation of mGP-i within tumor tissues. In an orthotopic syngeneic pancreatic tumor mouse model, mGP-i treatment significantly reduced tumor burden and metastasis compared with the control. Immunohistochemical analysis of mGP-i-treated tumors revealed reduced fibrosis and lower expression of the proliferation marker Ki-67, alongside increased TUNEL-positive cells, indicating apoptosis. Moreover, E-cadherin expression increased, while vimentin expression decreased, suggesting a transition toward a less invasive phenotype with reduced metastatic potential. These findings highlight mGP-i as a promising platform for tumor-targeted combination therapies in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.